Human MAP4K4/FLH21957/HEL-S-31 ORF/cDNA clone-Adenovirus plasmid (NM_001242559.2)

Cat. No.: pGMAD000919
Size: 10 µg
Concentration: generally 0.5ug/ul, usually not less than 0.3ug/ul
Leading Time: 3-7 working days

Pre-made Human MAP4K4/FLH21957/HEL-S-31 adenoviral expression plasmid for MAP4K4 adenovirus packaging, MAP4K4 adenovirus.

Our GM-Adenovirus vector is optimized with the GMVC-modified Adeasy adenovirus packaging system. Find more about the GMVC-modified adenovirus packaging system.

pdf Datasheet
pdf MSDS
pdf Terms of Use
Target products collection

Go to MAP4K4/FLH21957 products collection>>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

Purchase
Shipping fee: Limited-time free
For payment issues, contact us.


Product Description

Catalog ID pGMAD000919
Gene Name MAP4K4
Accession Number NM_001242559.2
Gene ID 9448
Species Human
Product Type Adenovirus plasmid (overexpression)
Insert Length 3720 bp
Gene Alias FLH21957,HEL-S-31,HGK,MEKKK4,NIK
Fluorescent Reporter EGFP
Mammalian Cell Selection Null
Fusion Tag MYC (C-Terminal)
Promoter EF1
Resistance Kanamycin
ORF Nucleotide Sequence ATGGCGAACGACTCCCCTGCAAAAAGTCTGGTGGACATCGACCTCTCCTCCCTGCGGGATCCTGCTGGGATTTTTGAGCTGGTGGAAGTGGTTGGAAATGGCACCTATGGACAAGTCTATAAGGGTCGACATGTTAAAACGGGTCAGTTGGCAGCCATCAAAGTTATGGATGTCACTGAGGATGAAGAGGAAGAAATCAAACTGGAGATAAATATGCTAAAGAAATACTCTCATCACAGAAACATTGCAACATATTATGGTGCTTTCATCAAAAAGAGCCCTCCAGGACATGATGACCAACTCTGGCTTGTTATGGAGTTCTGTGGGGCTGGGTCCATTACAGACCTTGTGAAGAACACCAAAGGGAACACACTCAAAGAAGACTGGATCGCTTACATCTCCAGAGAAATCCTGAGGGGACTGGCACATCTTCACATTCATCATGTGATTCACCGGGATATCAAGGGCCAGAATGTGTTGCTGACTGAGAATGCAGAGGTGAAACTTGTTGACTTTGGTGTGAGTGCTCAGCTGGACAGGACTGTGGGGCGGAGAAATACGTTCATAGGCACTCCCTACTGGATGGCTCCTGAGGTCATCGCCTGTGATGAGAACCCAGATGCCACCTATGATTACAGAAGTGATCTTTGGTCTTGTGGCATTACAGCCATTGAGATGGCAGAAGGTGCTCCCCCTCTCTGTGACATGCATCCAATGAGAGCACTGTTTCTCATTCCCAGAAACCCTCCTCCCCGGCTGAAGTCAAAAAAATGGTCGAAGAAGTTTTTTAGTTTTATAGAAGGGTGCCTGGTGAAGAATTACATGCAGCGGCCCTCTACAGAGCAGCTTTTGAAACATCCTTTTATAAGGGATCAGCCAAATGAAAGGCAAGTTAGAATCCAGCTTAAGGATCATATAGATCGTACCAGGAAGAAGAGAGGCGAGAAAGATGAAACTGAGTATGAGTACAGTGGGAGTGAGGAAGAAGAGGAGGAAGTGCCTGAACAGGAAGGAGAGCCAAGTTCCATTGTGAACGTGCCTGGTGAGTCTACTCTTCGCCGAGATTTCCTGAGACTGCAGCAGGAGAACAAGGAACGTTCCGAGGCTCTTCGGAGACAACAGTTACTACAGGAGCAACAGCTCCGGGAGCAGGAAGAATATAAAAGGCAACTGCTGGCAGAGAGACAGAAGCGGATTGAGCAGCAGAAAGAACAGAGGCGACGGCTAGAAGAGCAACAAAGGAGAGAGCGGGAAGCTAGAAGGCAGCAGGAACGTGAACAGCGAAGGAGAGAACAAGAAGAAAAGAGGCGTCTAGAGGAGTTGGAGAGAAGGCGCAAAGAAGAAGAGGAGAGGAGACGGGCAGAAGAAGAAAAGAGGAGAGTTGAAAGAGAACAGGAGTATATCAGGCGACAGCTAGAAGAGGAGCAGCGGCACTTGGAAGTCCTTCAGCAGCAGCTGCTCCAGGAGCAGGCCATGTTACTGGAGTGCCGATGGCGGGAGATGGAGGAGCACCGGCAGGCAGAGAGGCTCCAGAGGCAGTTGCAACAAGAACAAGCATATCTCCTGTCTCTACAGCATGACCATAGGAGGCCGCACCCGCAGCACTCGCAGCAGCCGCCACCACCGCAGCAGGAAAGGAGCAAGCCAAGCTTCCATGCTCCCGAGCCCAAAGCCCACTACGAGCCTGCTGACCGAGCGCGAGAGGTGGAAGATAGATTTAGGAAAACTAACCACAGCTCCCCTGAAGCCCAGTCTAAGCAGACAGGCAGAGTATTGGAGCCACCAGTGCCTTCCCGATCAGAGTCTTTTTCCAATGGCAACTCCGAGTCTGTGCATCCCGCCCTGCAGAGACCAGCGGAGCCACAGGTTCCTGTGAGAACAACATCTCGCTCCCCTGTTCTGTCCCGTCGAGATTCCCCACTGCAGGGCAGTGGGCAGCAGAATAGCCAGGCAGGACAGAGAAACTCCACCAGTATTGAGCCCAGGCTTCTGTGGGAGAGAGTGGAGAAGCTGGTGCCCAGACCTGGCAGTGGCAGCTCCTCAGGGTCCAGCAACTCAGGATCCCAGCCCGGGTCTCACCCTGGGTCTCAGAGTGGCTCCGGGGAACGCTTCAGAGTGAGATCATCATCCAAGTCTGAAGGCTCTCCATCTCAGCGCCTGGAAAATGCAGTGAAAAAACCTGAAGATAAAAAGGAAGTTTTCAGACCCCTCAAGCCTGCTGATCTGACCGCACTGGCCAAAGAGCTTCGAGCAGTGGAAGATGTACGGCCACCTCACAAAGTAACGGACTACTCCTCATCCAGTGAGGAGTCGGGGACGACGGATGAGGAGGACGACGATGTGGAGCAGGAAGGGGCTGACGAGTCCACCTCAGGACCAGAGGACACCAGAGCAGCGTCATCTCTGAATTTGAGCAATGGTGAAACGGAATCTGTGAAAACCATGATTGTCCATGATGATGTAGAAAGTGAGCCGGCCATGACCCCATCCAAGGAGGGCACTCTAATCGTCCGCCAGACTCAGTCCGCTAGTAGCACACTCCAGAAACACAAATCTTCCTCCTCCTTTACACCTTTTATAGACCCCAGATTACTACAGATTTCTCCATCTAGCGGAACAACAGTGACATCTGTGGTGGGATTTTCCTGTGATGGGATGAGACCAGAAGCCATAAGGCAAGATCCTACCCGGAAAGGCTCAGTGGTCAATGTGAATCCTACCAACACTAGGCCACAGAGTGACACCCCGGAGATTCGTAAATACAAGAAGAGGTTTAACTCTGAGATTCTGTGTGCTGCCTTATGGGGAGTGAATTTGCTAGTGGGTACAGAGAGTGGCCTGATGCTGCTGGACAGAAGTGGCCAAGGGAAGGTCTATCCTCTTATCAACCGAAGACGATTTCAACAAATGGACGTACTTGAGGGCTTGAATGTCTTGGTGACAATATCTGGCAAAAAGGATAAGTTACGTGTCTACTATTTGTCCTGGTTAAGAAATAAAATACTTCACAATGATCCAGAAGTTGAGAAGAAGCAGGGATGGACAACCGTAGGGGATTTGGAAGGATGTGTACATTATAAAGTTGTAAAATATGAAAGAATCAAATTTCTGGTGATTGCTTTGAAGAGTTCTGTGGAAGTCTATGCGTGGGCACCAAAGCCATATCACAAATTTATGGCCTTTAAGTCATTTGGAGAATTGGTACATAAGCCATTACTGGTGGATCTCACTGTTGAGGAAGGCCAGAGGTTGAAAGTGATCTATGGATCCTGTGCTGGATTCCATGCTGTTGATGTGGATTCAGGATCAGTCTATGACATTTATCTACCAACACATATCCAGTGTAGCATCAAACCCCATGCAATCATCATCCTCCCCAATACAGATGGAATGGAGCTTCTGGTGTGCTATGAAGATGAGGGGGTTTATGTAAACACATATGGAAGGATCACCAAGGATGTAGTTCTACAGTGGGGAGAGATGCCTACATCAGTAGCATATATTCGATCCAATCAGACAATGGGCTGGGGAGAGAAGGCCATAGAGATCCGATCTGTGGAAACTGGTCACTTGGATGGTGTGTTCATGCACAAAAGGGCTCAAAGACTAAAATTCTTGTGTGAACGCAATGACAAGGTGTTCTTTGCCTCTGTTCGGTCTGGTGGCAGCAGTCAGGTTTATTTCATGACCTTAGGCAGGACTTCTCTTCTGAGCTGGTAG
ORF Protein Sequence MANDSPAKSLVDIDLSSLRDPAGIFELVEVVGNGTYGQVYKGRHVKTGQLAAIKVMDVTEDEEEEIKLEINMLKKYSHHRNIATYYGAFIKKSPPGHDDQLWLVMEFCGAGSITDLVKNTKGNTLKEDWIAYISREILRGLAHLHIHHVIHRDIKGQNVLLTENAEVKLVDFGVSAQLDRTVGRRNTFIGTPYWMAPEVIACDENPDATYDYRSDLWSCGITAIEMAEGAPPLCDMHPMRALFLIPRNPPPRLKSKKWSKKFFSFIEGCLVKNYMQRPSTEQLLKHPFIRDQPNERQVRIQLKDHIDRTRKKRGEKDETEYEYSGSEEEEEEVPEQEGEPSSIVNVPGESTLRRDFLRLQQENKERSEALRRQQLLQEQQLREQEEYKRQLLAERQKRIEQQKEQRRRLEEQQRREREARRQQEREQRRREQEEKRRLEELERRRKEEEERRRAEEEKRRVEREQEYIRRQLEEEQRHLEVLQQQLLQEQAMLLECRWREMEEHRQAERLQRQLQQEQAYLLSLQHDHRRPHPQHSQQPPPPQQERSKPSFHAPEPKAHYEPADRAREVEDRFRKTNHSSPEAQSKQTGRVLEPPVPSRSESFSNGNSESVHPALQRPAEPQVPVRTTSRSPVLSRRDSPLQGSGQQNSQAGQRNSTSIEPRLLWERVEKLVPRPGSGSSSGSSNSGSQPGSHPGSQSGSGERFRVRSSSKSEGSPSQRLENAVKKPEDKKEVFRPLKPADLTALAKELRAVEDVRPPHKVTDYSSSSEESGTTDEEDDDVEQEGADESTSGPEDTRAASSLNLSNGETESVKTMIVHDDVESEPAMTPSKEGTLIVRQTQSASSTLQKHKSSSSFTPFIDPRLLQISPSSGTTVTSVVGFSCDGMRPEAIRQDPTRKGSVVNVNPTNTRPQSDTPEIRKYKKRFNSEILCAALWGVNLLVGTESGLMLLDRSGQGKVYPLINRRRFQQMDVLEGLNVLVTISGKKDKLRVYYLSWLRNKILHNDPEVEKKQGWTTVGDLEGCVHYKVVKYERIKFLVIALKSSVEVYAWAPKPYHKFMAFKSFGELVHKPLLVDLTVEEGQRLKVIYGSCAGFHAVDVDSGSVYDIYLPTHIQCSIKPHAIIILPNTDGMELLVCYEDEGVYVNTYGRITKDVVLQWGEMPTSVAYIRSNQTMGWGEKAIEIRSVETGHLDGVFMHKRAQRLKFLCERNDKVFFASVRSGGSSQVYFMTLGRTSLLSW

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    Category Cat No. Products Name
    Target Antibody GM-Tg-g-T71367-Ab Anti-MAP4K4 monoclonal antibody
    Target Antigen GM-Tg-g-T71367-Ag MAP4K4 protein
    ORF Viral Vector pGMAD000919 Human MAP4K4 Adenovirus plasmid
    ORF Viral Vector pGMPC001621 Human MAP4K4 Mammalian (Non-Viral Vector) plasmid
    ORF Viral Vector vGMAD000919 Human MAP4K4 Adenovirus particle


    Target information

    Target ID GM-T71367
    Target Name MAP4K4
    Gene ID 9448, 26921, 716595, 301363, 101081214, 481331, 509109, 100058919
    Gene Symbol and Synonyms 9430080K19Rik,FLH21957,HEL-S-31,HGK,MAP4K4,MEKKK4,NIK
    Uniprot Accession O95819
    Uniprot Entry Name M4K4_HUMAN
    Protein Sub-location Introcelluar Protein
    Category Therapeutics Target
    Disease Not Available
    Gene Ensembl ENSG00000071054
    Target Classification Kinase

    The protein encoded by this gene is a member of the serine/threonine protein kinase family. This kinase has been shown to specifically activate MAPK8/JNK. The activation of MAPK8 by this kinase is found to be inhibited by the dominant-negative mutants of MAP3K7/TAK1, MAP2K4/MKK4, and MAP2K7/MKK7, which suggests that this kinase may function through the MAP3K7-MAP2K4-MAP2K7 kinase cascade, and mediate the TNF-alpha signaling pathway. Alternatively spliced transcript variants encoding different isoforms have been identified. [provided by RefSeq, Jul 2008]



    About GMVC

    GDU

    GMVC (GM Vector Core) is GeneMedi’s unique platform for QbD Viral vectors Processes development and manufacturing. In GMVC, our core expertise lies in the tailored production of viral vectors, including adeno-associated virus (AAV), lentivirus, and adenovirus. Our state-of-the-art facilities are equipped for scalable manufacturing, ensuring high-quality viral vector production to meet both research and therapeutic needs. Our expert team specializes in process development, leveraging innovative technology and extensive industry knowledge to provide clients with tailored solutions that exceed expectations. GMVC will be the ideal partner for scientists and healthcare professionals seeking reliable and efficient viral vector production services.